Reuters quoted sources that when China ’s anti -corruption continued to upgrade, the Shanghai Stock Exchange urged banking institutions to pay close attention to the marketing behavior of Chinese drug and medical equipment manufacturers seeking the first public offering (IPO).
According to Reuters on Monday (August 14), the Shanghai Stock Exchange issued an internal publication at the end of July, which requires investment banking institutions and lawyersRegulations and legitimacy.
Two bank sources familiar with the issue confirmed the information to Reuters.The Shanghai Stock Exchange refused to comment on the matter.
Since the four departments of China National Medical Insurance Bureau and the Ministry of Finance jointly issued a notice on July 15th, since the thorough investigation of various types of illegal and illegal acts in the pharmaceutical field, at least 20 provinces have stated that they will conduct in -depth medical anti -corruption.
According to Chinese media statistics, as of August 12, at least 176 hospitals and secretaries across the country were investigated, which doubled over 88 people in 2022.
